Next Article in Journal
Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women
Next Article in Special Issue
Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses
Previous Article in Journal
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
Previous Article in Special Issue
Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

1
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
2
Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
3
Faculty of Science, Tanta University, Tanta 31527, Egypt
4
Department of Transplantation and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
5
Department of Otolaryngology Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
6
Takara Bio Inc., Kusatsu, Shiga 525-0028, Japan
7
Office of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2018, 10(10), 356; https://doi.org/10.3390/cancers10100356
Received: 18 July 2018 / Revised: 10 September 2018 / Accepted: 11 September 2018 / Published: 26 September 2018
(This article belongs to the Special Issue Oncolytic Virotherapy)
  |  
PDF [306 KB, uploaded 26 September 2018]
  |  

Abstract

Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic®) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpaturev—C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. Moreover, in glioma, several OVs have clearly demonstrated both safety and a promising efficacy in the phase I clinical trials. Additionally, the safety of several OVs, such as pelareorep (Reolysin®), proved their safety and efficacy in combination with paclitaxel in breast cancer patients, but the outcomes of OVs as monotherapy against breast cancer have not provided a clear therapeutic strategy for OVs. The clinical trials of OVs against pancreatic cancer have not yet demonstrated efficacy as either monotherapy or as part of combination therapy. However, there are several oncolytic viruses that have successfully proved their efficacy in different preclinical models. In this review, we mainly focused on the oncolytic viruses that transitioned into clinical trials against melanoma, glioma, pancreatic, and breast cancers. Hence, we described the current status and future prospects of OVs clinical trials against melanoma, glioma, pancreatic, and breast cancers. View Full-Text
Keywords: oncolytic viruses; clinical trials; melanoma; glioma; pancreatic; breast cancer clinical trials oncolytic viruses; clinical trials; melanoma; glioma; pancreatic; breast cancer clinical trials
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Eissa, I.R.; Bustos-Villalobos, I.; Ichinose, T.; Matsumura, S.; Naoe, Y.; Miyajima, N.; Morimoto, D.; Mukoyama, N.; Zhiwen, W.; Tanaka, M.; Hasegawa, H.; Sumigama, S.; Aleksic, B.; Kodera, Y.; Kasuya, H. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers 2018, 10, 356.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top